« Return to News | Drug Sponsors

Fate Therapeutics names Christian Weyer president, CEO

Monday, October 15, 2012 11:44 AM

San Diego, Calif.-based Fate Therapeutics has appointed Christian Weyer, M.D., M.A.S., president and CEO, and elected him to the board of directors, effective immediately.

Previously, Dr. Weyer spent 12 years with Amylin Pharmaceuticals, most recently as senior vice president of R&D, until its acquisition by Bristol-Myers Squibb in August 2012.

William H. Rastetter, a partner at Venrock who has served as Fate's interim CEO since November 2011, will remain chairman of the board of directors.

"Fate Therapeutics is pioneering innovative strategies to harness the therapeutic potential of adult stem cell biology, targeting disease areas of high unmet need that have not been adequately addressed by other pharmaceutical modalities," said Dr. Weyer.  "I am excited to join Fate as we are well-poised to accelerate the advancement of key programs, including ProHema, which may enable a new treatment paradigm for patients undergoing hematopoietic stem cell transplantation."

At Amylin, Dr. Weyer contributed to the development, approval and commercialization of several first-in-class diabetes medicines.  Prior to Amylin, Dr. Weyer spent three years with the National Institutes of Health, NIDDK, in Phoenix, where he conducted clinical research on the pathogenesis of obesity and type 2 diabetes.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.